Atmo SmartPill Comparison in Gastroparetic and Slow Transit Constipation Patients
NCT ID: NCT04977063
Last Updated: 2023-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53 participants
INTERVENTIONAL
2021-08-15
2023-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
NCT05718505
Evaluation of Gastrointestinal Motility With SmartPill
NCT01159002
A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old
NCT00682877
A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
NCT00128284
Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects
NCT06854120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The SmartPill measures pH and offers gold-standard measurements of gastrointestinal transit times. To validate the ability of the Atmo Capsule to measure gastrointestinal transit time, this device will be compared to the SmartPill. This will allow the equivalence of these two devices in gastrointestinal transit measurements to be evaluated.
This study aims to compare gastrointestinal transit times using immediately sequential ingestion of the SmartPill and Atmo capsule in patients with gastrointestinal motility disorders. A total of 60 participants diagnosed with either gastroparesis (n=30) or slow transit constipation (n=30) will be recruited by advertisement (via online support group pages, such as Gastroparesis Australia) and word-of-mouth. Potential participants will be screened for eligibility. Suitable individuals will be sent a Participant Information Sheet and Consent Form for review. Participants will be asked to stop proton pump inhibitors, histamine receptor blockers and antacids 3 days prior to the study and during the study. Medications that affect gastric motility will also be stopped 48 hours before the start of the study and during the study. Following an overnight fast, participants will attend the Macarthur Clinical School, Western Sydney University, where the Principal Investigator (Dr Jerry Zhou) will review the Patient Information Sheet with each participant and obtain informed written consent. Participants will then be asked to consume a cereal bar with 200mL of water. Participants will subsequently ingest the SmartPill and Atmo capsule. The order of swallowing these devices will be randomised with a computer-generated list. Participants will be monitored for 15 minutes post-ingestion. Subjects will then fast for the next 6 hours, after which they will consume their normal meals for the rest of the day. The data receiver for both the SmartPill and Atmo capsule will be worn or kept within 1.5 metres of the body until passage of the capsule has been confirmed by observation in the toilet bowl or signal loss from both capsules after a bowel movement.
Adverse events, bowel movements and the presence of gastrointestinal symptoms will be recorded in a digital diary (as part of the Atmo receiver system) whilst the Atmo capsule is in the body. Once both devices have passed from the body, participants will attend Macarthur Clinical School, where receivers will be returned and an investigator will review the digital diary with them.The investigator will follow up with the participant via phone or email approximately one week after the study to enquire about symptoms and adverse effects.
For the SmartPill, anatomical landmarks will be identified by changes in pH profiles along the gastrointestinal tract as previously reported in the literature. More specifically, gastric emptying time will be defined by the time of capsule ingestion to the presence of a sharp rise in pH (more than three units), where the capsule passes from an acidic environment (pH ≤4) in the stomach to a more basic environment (pH \>6) in the duodenum. Small intestinal transit will be determined by the time between the end of gastric emptying and identification of the ileo-caecal junction (a fall in ≥1 pH unit distal to gastric emptying). Colonic transit time will be defined as the time from ileocaecal junction to exit from the body. Whole gut transit time will be calculated as time of oral ingestion to exit from the body.
For the Atmo capsule, oxygen profiles will be used to characterise gastric emptying, small intestinal and colonic transit. Whole gut transit time will be calculated based on a change in temperature from exiting the body. The primary end-points of this study will be the agreement between gastric emptying, small intestinal and colonic transit times generated by the gas-sensing capsule vs wireless pH-motility. Statistical analysis with linear regression and by degrees of agreement (Bland-Altman tests) of measurements between the two devices will address these end-points. More subjects will be studied pending the results of this pilot study. The results, conduct and reporting of this study will conform to the STARD 2015 guidelines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SmartPill and Atmo capsule
The SmartPill and Atmo gas capsule will be tested simultaneously. This will allow the ability of the Atmo gas capsule to measure gastrointestinal transit time to be compared to the SmartPill. The order of swallowing will be randomised using a computer-generated list. The two capsules will be swallowed within 5 minutes of each other
Atmo gas capsule
The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
SmartPill
The SmartPill measures the capsules location and motility/transit times through pH sensing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atmo gas capsule
The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
SmartPill
The SmartPill measures the capsules location and motility/transit times through pH sensing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with slow transit constipation for at least 12 weeks (exclusion of constipation caused by structural abnormalities with colonoscopy, and confirmation of slow transit by 'marker studies' such as scintigraphy, radiolabelled or opaque X-ray study). Participant would have at least 1 bowel motion per week (either assisted or unassisted by medication).
* No evidence of metabolic disease (hypothyroidism, uncontrolled diabetes \[hemoglobin A1c \>10% within the past 6 months\], electrolyte imbalance).
* An endoscopy or gastrointestinal barium series within the past 3 years showing no organic disease that is potentially causative of symptoms.
* Ability to stop medications that may alter gastric pH (such as proton pump inhibitors) for 3 days prior to and during study.
* Ability to stop medications that may alter gastrointestinal motility (GLP-1 angonists, anticholinergics, cannabinoids, metformin, antispasmodic, prokinetics) for 3 days prior to and during study.
* Ability to stop antibiotic, probiotic and, prebiotic supplements 7 days before prior to and during study.
* Ability to stop laxatives (docusate, lactulose, sorbitol, senna, bisacodyl), suppositories (glycerin), and enema 3 days prior to and during the study.
* Does not require a MRI scan during the duration of this study
Exclusion Criteria
* History of diverticulitis, diverticular stricture, and other intestinal strictures
* Chronic daily use of nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, etc.)
* Pregnant or nursing
* Patients on long-acting glucagon-like peptide (GLP-1)
* Implantable devices (e.g. pacemaker, defibrillator) \[continuous glucose monitors are permitted\].
* History of bezoar formation
* Dysphagia to solid foods
* Gastric/jejunal feeding tubes
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Western Sydney
OTHER
Atmo Biosciences Pty Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerry Zhou, PhD BSc
Role: PRINCIPAL_INVESTIGATOR
School of Medicine, Western Sydney University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Blacktown Hospital
Blacktown, New South Wales, Australia
School of Medicine, Western Sydney University
Campbelltown, New South Wales, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ETH01064
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.